Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 5Completed 5Terminated 4Not yet recruiting 2Active not recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2Thoracic 1Gastrointestinal 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 26Lung Neoplasms 5Small Cell Lung Carcinoma 2Pancreatic Neoplasms 2Neoplasm Metastasis 2NSCLC 2Brain Neoplasms 2Solid Tumor Cancer 1Non-squamous Non-small Cell Lung Cancer 1Non-small Cell Lung Cancer Metastatic 1Non Squamous Non-small Cell Lung Cancer 1Neoplasms 1Mesothelioma, Malignant 1Meningeal Carcinomatosis 1Melanoma 1Lymphatic Metastasis 1Lung Non-Squamous Non-Small Cell Carcinoma 1Lung Diseases, Interstitial 1Gastrointestinal Neoplasms 1Esophageal Neoplasms 1Disease Progression 1Diabetes Mellitus, Insulin-Dependent, 12 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma 1Advanced Solid Tumor 1Adenocarcinoma of Lung 1

Interventions

aflutinib 3Saline Solution 3Radiotherapy 3Temozolomide 2Receptors, Interleukin-8B 2Radiosurgery 2Pemetrexed 2Memantine 2Indocyanine Green 2Dexmedetomidine 2Cyclophosphamide 2Carboplatin 2Blood Specimen Collection 2Bevacizumab 2Aminolevulinic Acid 2urinastatin 1trastuzumab deruxtecan 1tovorafenib 1sacituzumab govitecan 1posaconazole 1pembrolizumab 1peginterferon alfa-2b 1osimertinib 1neratinib 1montelukast 1gallium maltolate 1fludarabine 1dalpiciclib 1asciminib 1anlotinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × Brain Neoplasms × Pemetrexed × Clear all
NCT07492680 2026-03-25

A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

Bristol-Myers Squibb

Phase 2 Not yet recruiting
260 enrolled
CNSDermatologicGastrointestinal

Brain Neoplasms, Melanoma, Pancreatic Neoplasms

NCT07365410 2026-01-26

Furmonertinib 160mg vs 80mg + Chemotherapy in EGFR-Mutated NSCLC With Brain Metastases: Efficacy and Safety Study

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Not yet recruiting
60 enrolled
CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡